ICER: New Cholesterol Drugs Highly Overpriced

Share this content:
ICER: New Cholesterol Drugs Highly Overpriced
ICER: New Cholesterol Drugs Highly Overpriced

WEDNESDAY, Sept. 9, 2015 (HealthDay News) -- Two newly approved medications to treat high cholesterol are extremely overpriced compared to the health benefits they give to patients, a new analysis finds. The drugs in question, Repatha (evolocumab) and Praluent (alirocumab), currently cost more than $14,000 per year, and because millions of Americans have high cholesterol, costs could be overwhelming, according to The New York Times.

The new report, from the nonprofit Institute for Clinical and Economic Review (ICER), said that an annual cost of $3,615 to $4,811 would be more in line with the value the medications are expected to provide in preventing heart attacks and deaths. However, at current pricing, "even if these drugs were used in just over 25 percent of eligible patients, then employers, insurers, and patients would need to spend on average more than $20 billion a year," Steven Pearson, M.D., the founder and president of ICER, said in an institute news release.

In response, Amgen, the maker of Repatha, said in a statement: "We are concerned that ICER's review does not place value on addressing a significant unmet medical need, and its short-term budgetary focus will be used to create access barriers to innovative medicines like Repatha for appropriate patients." Regeneron Pharmaceuticals, which has partnered with Sanofi to make Praluent, said it had not yet had time to review the new report. But a spokeswoman told The Times that "these calculations are complex, and a robust and open peer-review process is essential."

According to The Times, the exact benefit of Repatha and Praluent for heart patients may not be known until the results of large clinical trials arrive in 2017.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »